Our core data analytics technology has been developed and refined by our founders since 2008. This technology has been used in eight clinical studies and has been the core tool to perform medical research described in more than 20 peer-reviewed scientific publications.


An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.


Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.


Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.


Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.


Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.


Integrated genomic and epigenomic analysis of breast cancer brain metastasis.


Long insert whole genome sequencing for copy number variant and translocation detection.


Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.


Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs.


CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.


Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.


Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma.


Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.


Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples.